...
首页> 外文期刊>International journal of medical microbiology: IJMM >Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins
【24h】

Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins

机译:用于表达和分泌防御素的重组大肠杆菌Nissle 1917(EcN)菌株的构建

获取原文
获取原文并翻译 | 示例
           

摘要

The probiotic Escherichia coli strain Nissle 1917 (EcN) is one of the few probiotics licensed as a medication in several countries. Best documented is its effectiveness in keeping patients suffering from ulcerative colitis (UC) in remission. This might be due to its ability to induce the production of human β-defensin 2 (HBD2) in a flagellin-dependent way in intestinal epithelial cells. In contrast to ulcerative colitis, for Crohn's disease (CD) convincing evidence is lacking that EcN might be clinically effective, most likely due to the genetically based inability of sufficient defensin production in CD patients. As a first step in the development of an alternative approach for the treatment of CD patients, EcN strains were constructed which were able to produce human α-defensin 5 (HD5) or β-defensin 2 (HBD2). For that purpose, codon-optimized defensin genes encoding either the proform with the signal sequence of human α-defensin 5 (HD5) or the gene encoding HBD2 with or without the signal sequence were cloned in an expression vector plasmid under the control of the T7 promoter. Synthesis of the encoded defensins was shown by Western blots after induction of expression and lysis of the recombinant EcN strains. Recombinant mature HBD2 with an N-terminal His-tag could be purified by Ni-column chromatography and showed antimicrobial activity against E. coli, Salmonella enterica serovar Typhimurium and Listeria monocytogenes. In a second approach, that part of the HBD2 gene which encodes mature HBD2 was fused with the yebF gene. The resulting fusion protein YebFMHBD2 was secreted from the encoding EcN mutant strain after induction of expression. Presence of YebFMHBD2 in the medium was not the result of leakage from the bacterial cells, as demonstrated in the spent culture supernatant by Western blots specific for β-galactosidase and maltose-binding protein. The dialyzed and concentrated culture supernatant inhibited the growth of E. coli, S. enterica serovar Typhimurium and L. monocytogenes in radial diffusion assays as well as in liquid culture. This demonstrates EcN to be a suitable probiotic E. coli strain for the production of certain defensins.
机译:益生菌大肠杆菌菌株Nissle 1917(EcN)是在几个国家中被许可用作药物的少数益生菌之一。最好的记录是它在保持溃疡性结肠炎(UC)患者缓解方面的有效性。这可能是由于它具有以鞭毛蛋白依赖性方式在肠上皮细胞中诱导人β-防御素2(HBD2)产生的能力。与溃疡性结肠炎相反,对于克罗恩氏病(CD),缺乏令人信服的证据表明EcN在临床上可能是有效的,这很可能是由于CD患者无法产生足够的防御素而基于遗传的原因。作为开发治疗CD患者的替代方法的第一步,构建了能够产生人α-防御素5(HD5)或β-防御素2(HBD2)的EcN菌株。为此,将编码具有人α-防御素5(HD5)信号序列的形式的密码子优化的防御素基因或具有或不具有信号序列的编码HBD2的基因克隆到表达载体质粒中,由T7控制启动子。诱导表达和裂解重组EcN菌株后,Western印迹显示编码的防御素的合成。具有N末端His标签的重组成熟HBD2可以通过镍柱色谱法纯化,并显示出对大肠杆菌,肠炎沙门氏菌血清鼠伤寒沙门氏菌和单核细胞增生李斯特菌的抗菌活性。在第二种方法中,将编码成熟HBD2的HBD2基因部分与yebF基因融合。诱导表达后,从编码的EcN突变株中分泌得到的融合蛋白YebFMHBD2。培养基中YebFMHBD2的存在不是细菌细胞渗漏的结果,正如用过的培养物上清液对β-半乳糖苷酶和麦芽糖结合蛋白具有特异性的蛋白质印迹所证明的那样。透析和浓缩的培养上清液在径向扩散测定和液体培养中均抑制了大肠杆菌,肠炎沙门氏菌血清鼠伤寒杆菌和单核细胞增生李斯特菌的生长。这证明EcN是用于产生某些防御素的合适的益生菌大肠杆菌菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号